| Ytd | 77.19% | |
| 1y | 46.80% |
| Open | 0.97 | Prev Close | 0.95 | Low | 0.96 | High | 1.02 | Mkt Cap | 12.93M |
| Vol | 240.15K | Avg Vol | 215.00K | EPS | -0.98 | P/E | N/A | Forward P/E | -1.17 |
| Beta | 0.51 | Short Ratio | 0.08 | Inst. Own | 20.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 0.98 | 200-d Avg | 0.92 | 1yr Est | 11.50 |
Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates.
Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. Se
Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative B
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.41) per share which missed the analyst co
Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.48 per share which beat the analyst cons
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization an
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical
Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutica
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photody
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical
Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photod
Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst co
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch
All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, b
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Compa
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst co
Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® i
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the development and commercia
Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending
Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the pri
Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends paten
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.19) per share which beat the analyst cons
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(3.22) per share which missed the analyst co
First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol
Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up